HUGE —. Revenue will skyrocket. READ.
$VLRX announced the inclusion by the American Diabetes Association (ADA) of the use of a “disposable patch-like device” for insulin delivery in the new Diabetes Technology chapter of ADA’s annual Standards of Medical Care in Diabetes for 2019, published in Diabetes Care. The inclusion in this year’s Standards of Care marks the first time such a device has been incorporated in ADA’s current clinical practice recommendations.
“It is good news for patients and medical professionals that the ADA now includes disposable, patch-like devices in its annual Standards of Medical Care,” said John Timberlake, President and Chief Executive Officer of Valeritas. “Having a well respected organization like the ADA recognize the value of a disposable, patch-like device, such as V-Go, is significant.”
Clinical studies have consistently demonstrated that patients with type 2 diabetes who have switched from insulin injection therapy to the simple-to-use, wearable V-Go significantly lowered blood glucose with less insulin.
Studies have also demonstrated that use of V-Go for insulin therapy proved to be a more cost-effective delivery option compared to multiple daily injections using syringes or pens.
Standards of Care is an official ADA position, is authored by the ADA, and provides all of the ADA’s current clinical practice recommendations. To update the Standards of Care, the ADA’s Professional Practice Committee (PPC) performs an extensive clinical diabetes literature search, supplemented with input from ADA staff and the medical community at large.
AI
